Rutgers will have a mostly-new coaching staff on the defensive side of the ball during the 2026 season. Safety coach Vic Hall became the fifth defensive assistant to leave the Scarlet Knights this ...
Phase III is intended to generate meaningful biological data on potential drug compounds prioritized by YuvaBio’s classifier, which applies proprietary machine-learning methods to identify candidates ...
A year after a clutch of major pharmas threw their weight behind a new campaign devoted to addressing the serious health disparities facing Black breast cancer patients, “Care for HER” has been shown ...
US POINTER, a healthy lifestyle intervention, helped participants improve blood pressure regulation of blood flow to the brain, reduced sleep apnea respiratory events, and increased cognitive ...
For the second time in the span of 12 months, Rutgers is looking for a new defensive coordinator. Defensive coordinator Robb Smith was fired following the first year of his third stint with the ...
Contineum Therapeutics, Inc. (NASDAQ: CTNM) on Thursday shared topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist for relapsing-remitting multiple sclerosis (RRMS). RRMS ...
Argus (WMSM-915), the first ship of the heritage class of medium endurance offshore patrol cutters, enters the water during a christening ceremony in Panama City, Fla., Oct. 27, 2023. US Coast Guard ...
The U.S. Department of Education said Tuesday it’s developed six agreements to send many of its key functions to other federal agencies. A majority of the Education Department’s funding for K-12 ...
A new state report has cited a Stillwater-area substance abuse treatment program for more than 100 breaches of state law or rules, confirming what whistleblowers long suspected. Last summer, several ...
The Justice Department later said it would appeal, leaving the program known as SNAP in limbo. By Tony Romm Reporting from Washington A federal judge ordered the Trump administration on Thursday to ...
Takeda has given up on an AstraZeneca-partnered neurological disorder program after the therapy flunked a phase 2 study. The Japanese pharma had been evaluating the alpha-synuclein antibody, called ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results